Twenty-four patients aged 10.1 ± 4.5 (mean ± SD) years with recurrent paroxysmal supraventricular tachycardia underwent an electrophysiological study. Eleven patients had an overt and seven had a concealed accessory connection; six patients had no accessory connection. An orthodromic reciprocating tachycardia was inducible in 17 of 18 patients with an accessory connection, and an atrioventricular nodal reentrant tachycardia was inducible in four of six patients without accessory connection. After administration of propafenone, the sinus cycle length decreased. Intra-arterial, intranodal, and His-ventricle intervals and QRS duration increased. The atrial and ventricular effective refractory periods and anterograde and retrograde effective refractory periods of the atrioventricular node increased. The cycle length at which nodal second-degree block occurred increased. Of 18 patients with accessory connection, propafenone prolonged retrograde conduction in all, blocked anterograde conduction in five, and prolonged it in six. The drug terminated the orthodromic reciprocating tachycardia in all 17 patients and the atrioventricular nodal reentrant tachycardia in three of four patients. In three of four patients with atrioventricular nodal reentrant tachycardia and in 15 of 17 patients with orthodromic reciprocating tachycardia, the tachycardia was no longer inducible or nonsustained after propafenone. A follow-up of 26 ± 10 months revealed that the drug when orally administered to all patients prevented recurrences of tachycardia in 15 of 18 patients with and in four of six patients without accessory connection. The results of short-term drug testing with propafenone predict the response to long-term oral therapy with this drug.
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Pa aroxysmal supraventricular tachycardia is frequently observed in young children. In children, the appearance and duration of tachycardia paroxysms are unpredictable. Paroxysms may continue for years and may interfere with normal activities of the patients; therefore, a preventive treatment frequently is necessary for many years. 1-3 However, long-term therapy with conventional antiarrhythmic drugs is often disappointing; thus, new drugs are tried. Digitalis has been the most popular drug used in suppressing paroxysmal attacks of supraventricular tachycardia, but other drugs, such as verapamil or adenosine 5'-triphosphate, are effective.3-5 Propafenone, a drug with a membrane stabilizing effect, local anesthetic properties, weak ,8-blocking effects, and calcium antagonist effects,6-8 has proved successful in the treatment of supraventricular and ventricular arrhythmias in the adult human.9,10 Experience with this drug in children is limited." 112 The aim of this study is to assess the electrophysiological effects and clinical efficacy of propafenone in the shortand long-term management of children with recurrent paroxysmal supraventricular tachycardia. acid dehydrogenase, serum glutamicpyruvic transaminase, urea nitrogen, bilirubin, total protein, albumin, glucose, electrolytes, calcium, phosphorus, creatinine, uric acid, cholesterol, and triglycerides levels.
Twenty-four-hour Holter monitoring was performed in all patients before electrophysiological study, on the 6th day after beginning oral treatment with propafenone, and periodically during followup. All patients had normal hearts. Written, informed consent was obtained in all instances from parents. Fifteen patients had failed to respond to at least one of the following drugs: disopyramide, verapamil, ,3-blockers (metoprolol and pindolol), quinidine, flecainide, and amiodarone. Before the control electrophysiological study, all cardioactive medications were discontinued for a period exceeding three times their elimination half-lives. In three patients on amiodarone therapy, the drug withdrawal period was at least I month. The electrophysiological study was performed under sedation and began 45 minutes afer premedication with promethazine (1 mg/kg body wt) and meperidine (1 mg/kg body wt) administered intramuscularly. Intracardiac studies were performed with standard techniques.'3 In two patients, left atrial activity was recorded indirectly through the main pulmonary trunk,14 and in three patients, activity was recorded directly from the left atrium through a patent foramen ovale. The conventional definitions of conduction intervals and refractory periods were used. 13, 15 The effective refractory periods were obtained with a driven cycle length of 500 msec before and after propafenone administration. In one patient, the pacing cycle length was 400 msec. The diagnosis of reciprocating tachycardia due to an accessory atrioventricular connection was made by the following criteria: 1) eccentric retrograde atrial activation sequence; 2) preexcitation of the atrium during reciprocating tachycardia at a time when the His bundle was refractory'3.17; 3) prolongation of the ventriculoatrial interval during tachycardia when ipsilateral bundle branch block occurred'8; 4) minimum ventriculoatrial interval equal to or exceeding 70 msec22; or a combination of these four. The diagnosis of atrioventricular nodal reentrant tachycardia was made by standard criteria, 3'15'19-22 and it was based mainly on exclusion of the other causes.
Drug Administration
After baseline electrophysiological evaluation, propafenone was administered intravenously during continuous stable tachycardia. In three patients in whom the arrhythmia could not be induced, propafenone was administered during sinus rhythm. The dose (1.5 mg/kg body wt) was injected during a 3-minute period. The complete dose was administered whether or not termination of tachycardia occurred. Ten minutes after commencing drug infusion, the electrophysiological protocol was repeated. If the tachycardia persisted after this time interval, it was interrupted by artificial stimulation. In all patients, blood pressure was checked with a sphygmomanometer before and every 3 minutes for 15 minutes after drug administration. In 10 patients, the pulmonary capillary wedge pressure and mean pulmonary artery pressure were checked before and at 10 and 15 minutes after beginning intravenous administration of propafenone. The measurements were performed with a 6F or 7F Swan-Ganz catheter. Results are reported as mean value + SD. Statistical evaluation was performed by Student's t test for paired data.
Results
Eighteen patients had accessory connections with bidirectional conduction in 11 and retrograde conduction only in seven. In 17 patients, an orthodromic atrioventricular reentrant tachycardia was induced. In four of the six patients without accessory connections, an atrioventricular nodal reentrant tachycardia was induced. 
Effects of Propafenone on Electrophysiological Variables of Normal Cardiac Conduction System
Treatment with propafenone caused the sinus cycle length to decrease significantly. The conduction intervals (PA, AH, and HV) increased significantly as did the effective refractory period of atria, atrioventricular node, and ventricle (Table 1 ).
In three patients with ventricular preexcitation, the AH interval was not determined because the His potential was not visible. The HV interval and QRS duration were measured during sinus rhythm in 13 patients with narrow QRS and in seven with and six without an accessory connection. Effects on the Accessory Connection In five of the 11 patients with ventricular preexcitation, with an anterograde effective refractory period of accessory connection of 306+±48 msec (range, 270-390 msec), and with the shortest anterograde 1:1 conduction cycle length of 347 ± 44 msec (range, 290-400 msec), propafenone blocked the anterograde conduction in the accessory connection ( Table 2 ). In four patients, the anterograde effective refractory period increased from 247 + 10 msec (range, 240-260 msec) to 285 + 17 msec (range, 260-300 msec) (p<0.02), and maximal anterograde 1: 1 conduction increased from a mean cycle length of 241 ± 22 msec (range, 222-261 msec) to 318 + 102 msec (range, 231-462 msec) (p<0.05). In two patients, comparison of the anterograde effective refractory period of accessory connection before and after propafenone administration was limited by atrial refractoriness. In 12 of the 18 patients with an accessory connection, the retrograde effective refractory period increased from 259±36 msec (range, 220-310 msec) to 300 ±44 msec (range, 230-410 msec) (p<0.005), and maximal retrograde 1: 1 conduction increased from a mean cycle length of 273±46 msec (range, 240-375 msec) to 366±53 msec (range, 310-500 msec) (p<0.001). In the remaining six patients, comparison of the retrograde effective refractory period before and after propafenone treatment was not made because of ventricular refractoriness.
Effects on Orthodromic
Reciprocating Tachycardia An orthodromic reciprocating tachycardia was induced in 17 of the 18 patients. Propafenone blocked the retrograde limb of the circuit in 16 patients (Figure 1 and Table 3 ) and the anterograde limb in one. Termination occurred within 4.1 ± 1.1 minutes (range, 1.5-5 minutes) from the beginning of administration with a dose ranging from 0.75 to 1.5 mg/kg body wt. The cycle length of tachycardia was 307 ± 50 msec (range, 250-400 msec) in the control study and increased to 393±68 msec (range, 310-500 msec) (p<0.001) immediately before cessation. Prolongation of the cycle length of tachycardia was due to both increased conduction time in the retrograde limb (VA'), which increased from 126 ± 39 msec (range, 80-220 msec) to 171 ±44 msec (range, 115-275 msec) (p<0.001). The VA' interval was measured from the earliest recorded ventricular activity to the first rapid deflection in the bipolar atrial electrogram recorded at each site. The ante-01 FIGURE 1. Recordings from a 5-year-old patient with concealed left wall accessory connection. Orthodromic reciprocating tachycardia termination resulted from retrograde block in the accessory connection. Before termination, the tachycardia cycle length increased from 280 to 320 msec because of delay in ventricular to atrial conduction. A, intracardiac atrial electrogram; DCSE, distal coronary sinus electrogram; H, intracardiac His bundle deflection; HBE, His bundle electrogram; HRAE, high right atrial electrogram; V, ventricular depolarization; I, II, III, V], surface electrocardiographic leads. rograde conduction time (A'V) increased from 182±43 msec (range, 115-280 msec) to 221±66 msec (range, 115-355 msec) (p<0.001). After propafenone administration, tachycardia was still inducible in nine patients (53%) but with a longer cycle than the control value (311 ± 47 vs. 415 ± 65 msec), and in seven of these nine patients, the tachycardia was nonsustained (<30 seconds). In the remaining eight patients (47%), the tachycardia was no longer inducible. Thus, in 88% of patients, the tachycardia was either noninducible or nonsustained after propafenone infusion.
Effects on Atrioventricular Nodal Reentrant Tachycardia
The tachycardia was induced in four of the six patients without an accessory connection: two patients showed the typical pattern of common atrioventricular nodal reentry, and both had dual atrioventricular nodal pathways; two patients showed the uncommon type, and both had a smooth ventriculoatrial conduction curve. Propafenone blocked the tachycardia in the retrograde limb of the circuit in three patients (75%) ( Table 3 ). In the fourth patient, with common form, the tachycardia slowed and was terminated by premature stimulation 10 minutes after the beginning of drug administration. The cycle length of the tachycardia increased from 289 + 59 msec (range, 235-340 msec) to 407 ± 33 msec (range, 370-440 msec) (p<0.005). The anterograde conduction time (A'H), measured in the cycle preceding cessation of tachycardia, increased from 169 ± 128 msec (range, 55-280 msec) to 232± 131 msec (range, 120-370 msec) (p<0.01). The retrograde conduction time (HA') increased from 120 ± 69 msec (range, 60-185 msec) to 175 ± 101 msec (range, 60-270 msec) (NS). The arrhythmia was still inducible and sustained in one patient but with a longer cycle. In the other three patients, the tachycardia was no longer inducible.
Effects on Blood Pressure
In all patients, the systolic blood pressure decreased after propafenone administration; the decrease never exceeded 10 mm Hg. In 10 patients, the pulmonary capillary wedge pressure and mean pulmonary artery pressure did not show significant modifications (7 ± 3 vs. 8 ± 3 mm Hg and 12 ± 3 vs. 13±4 mm Hg, respectively). Long-term Efficacy All 24 patients received maintenance therapy with propafenone orally administered. The daily dosage, in two or three divided doses, was 14.3 ± 3.8 mg/kg body wt/day (range, 10-20 mg/kg body wt/ day). Follow-up assessment was by history of recurrence of symptoms, 12 lead electrocardiogram, and 24-hour ambulatory monitoring. Follow-up ranged from 10 to 30 months with a mean of 26±10 months. Among 17 patients with orthodromic reentrant tachycardia (Table 4) , 14 (82%) are at present asymptomatic, which includes seven patients with inducible but nonsustained tachycardia and seven with noninducible tachycardia after intravenous propafenone treatment. The remaining three patients had recurrences and were given other forms of treatment. Patient 18, with an accessory connection in whom the arrhythmia was noninducible in the basal and postpropafenone studies, was also asymptomatic. Of the three patients with nonreinducible atrioventricular nodal reentrant tachycardia, two (Table 4 ) were asymptomatic. The fourth patient with reinducible and sustained nodal tachycardia was also free of recurrences. Of the remaining two patients without accessory connections in whom the tachycardia was noninducible in the basal and postpropafenone studies, one was asymptomatic. On the whole, propafenone was efficacious in 66% of patients without an accessory connection. Side Effects A single patient experienced nausea and tremor within the first 2 days of therapy. These effects subsided when a reduced dosage was used. No abnormalities of hematological and biochemical indexes were noted during follow-up. No abnormalities of the size of the heart on chest radiograph or abnormalities of cardiac function as determined by echocardiogram (left ventricular shortening fraction) were found. Discussion Several studies in adult patients have shown that propafenone prolongs the effective refractory periods, slows the conduction in the various cardiac structures and in the accessory connections, and depresses the sinus automaticity and sinoatrial conduction. 23, 24 This study shows that similar modifications are present in children. At variance to that observed in the adult,10,24 we have noted a significant reduction of the sinus cycle length after intravenous injection of propafenone. This finding is in agreement with the data reported by Karagueuzian and others25 in anesthetized dogs treated with this drug. Those investigators attributed the increase of heart rate to increased reflex sympathetic activity secondary to decreased aortic blood pressure induced by the drug. A small variation of blood pressure that might have influenced the shortening of sinus cycle length has been observed among our patients. The change in the variables of excitation and conduction of the atrioventricular node induced by propafenone is the mechanism underlying the efficacy on atrioventricular nodal reentrant tachycardia. According to our experience, intravenous propafenone terminated 75% of paroxysms of atrioventricular nodal reentrant tachycardia as a result of blockade of the retrograde limb. Long-term drug therapy prevented recurrences in two of the three patients (66%) with atrioventricular nodal reentrant tachycardia that was noninducible after intravenous propafenone administration. In addition, both the increase of atrial and nodal effective refractory periods and the decrease of atrioventricular conduction might be helpful in preventing tachyarrhythmias arising in the atria and in limiting the ventricular response. 10 1 1 On the other hand, the depressant effect of propafenone on atrioventricular conduction demands particular caution in patients with atrioventricular or intraventricular conduction disturbance. The drug affected both anterograde and retrograde electrophysiological properties of accessory connections, slowing conduction and significantly increasing refractory periods. In five patients with an anterograde effective refractory period of 270 msec or greater, block of impulse in the accessory connection occurred.26 These electrophysiological effects make the drug extremely useful in the treatment and prevention of supraventricular tachyarrhythmias associated with a preexcitation. In this study, propafenone terminated the reciprocating tachycardia associated with an accessory connection in all 17 patients (100%), and in 16 of the patients, termination was due to effects on the retrograde limb of circuit. During long-term therapy, the drug prevented recurrences in 14 of the 15 patients (93%) with orthodromic tachycardia that was noninducible (seven patients) or nonsustained (seven patients) after intravenous administration of propafenone. Thus, it seems that favorable results of short-term drug testing with propafenone may be extrapolated to the long-term oral administration of this drug for treatment of supraventricular tachycardia in children. This is in agreement with similar findings in adults.27 Moreover, an inducible and nonsustained tachycardia after short-term propafenone administration does not seem to preclude long-term efficacy as verified in seven patients with orthodromic reciprocating tachycardia. This can be linked to possible modifications induced in the substrate of arrhythmias by active metabolites of the drug28,29 or by achievements of drug plasma level during long-term therapy at doses higher than intravenous administration, or by suppression of triggers. The place of propafenone in the treatment of pediatric arrhythmias will be determined by further experience and long-term follow-up. Recently, Garson and colleagues"1 have reported the results of use of propafenone for the short-term treatment of postoperative junctional ectopic tachycardia in seven children, and in all patients, the drug was successful in reducing the rate of tachycardia. Thus, the drug seems to have beneficial effects in suppressing automaticity. Our study shows that propafenone is a promising drug in the short-term treatment and in long-term prevention of paroxysmal supraventricular reciprocating tachycardia in children. The response during electrophysiological testing appears to predict the response to long-term oral therapy with propafenone. The presence of the drug in the body is well tolerated with only few side effects and may prove to be an alternative to more toxic antiarrhythmic drugs.30.31 However, studies have revealed a negative inotropic effect with propafenone, 32 33 a fact that should be considered when this drug is used in patients with structural heart disease or with depressed left ventricular function.
